We applied an artificial intelligence (AI) approach to a dataset of clinical and advanced multi-omic molecular features from patients with pancreatic adenocarcinoma to predict survival. The results reveal a tumor-type-agnostic platform that can identify parsimonious and robust clinical prediction biomarkers, catalyzing the vision to democratize precision oncology worldwide.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Park, W., Chawla, A. & O’Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851–862 (2021). A review article that presents an overview of PDAC, limitations of current therapies and clinically relevant biomarkers that underscore the aggressive nature of this disease.
Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J. Gastrointest. Oncol. 3, 105–119 (2012). This paper reports the clinical application of CA 19-9 as a tumor marker in PDAC and its limitations as a diagnostic and predictive biomarker.
Schreyer, D., Neoptolemos, J. P., Barry, S. T. & Bailey, P. Deconstructing pancreatic cancer using next generation-omic technologies-from discovery to knowledge-guided platforms for better patient management. Front. Cell Dev. Biol. 9, 795735 (2021). An article that presents current and future omic approaches and the need for integrative systems and machine learning applications to identify new biomarkers in PDAC.
Cao, L. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 184, 5031–5052.e5026 (2021). This paper presents an integrated proteogenomic characterization of PDAC that is a valuable resource for early detection, identification of new therapeutic targets and serves as a validation dataset.
The Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013). This paper presents comprehensive molecular data profiled by TCGA Research Network from a pan-cancer initiative, which includes PDAC.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Osipov, A. et al. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Nat. Cancer https://doi.org/10.1038/s43018-023-00697-7 (2024).
Rights and permissions
About this article
Cite this article
Artificial intelligence uses multi-omic data to predict pancreatic cancer outcomes. Nat Cancer 5, 226–227 (2024). https://doi.org/10.1038/s43018-023-00698-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00698-6
